RevoluGen: Annalisa Jenkins
RevoluGen has appointed Annalisa Jenkins as the company’s chair of the board of directors. Prior to joining RevoluGen, Jenkins served as the executive VP, head of global research and development, and a member of the pharmaceutical executive committee for Merck Serono. Before that, she had a 14-year career at Bristol-Myers Squibb as the senior VP and head of global medical affairs. Jenkins also currently serves as a board member of several healthcare companies including Affimed, AoBiome, Avrobio, Cocoon Biotech, Compass Pathways, Oncimmune, Ori Biotech, Perspectum, and Phaim Pharma along with various governmental, academic, and non-profit organizations positions in the U.K. and U.S. Jenkins holds a degree in medicine from St. Bartholomew’s Hospital, University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.